Save your seat for this upcoming webinar! In response to tighter margins, globalization and increasing regulatory complexity, sponsors have been embracing an outsourcing model using contract research organizations (CROs) to conduct scientific services for all phases of clinical research.
Title: Disrupting Clinical Operations with CRO Strategic Partnerships
As pharma increasing relies on CRO outsourcing in clinical research, relationships are becoming more strategic. The benefits of this approach will not come from simply increasing relationships with CROs, but in how sponsors leverage those relationships to introduce innovation into their workflows. Cue the rise of cloud-based technology solutions. Clinical Trials, the costliest stage in drug development, have much to benefit from leveraging the cloud to collaborate with partners and share views of key data trends and process metrics.
With so much at stake where do you start when considering the right long-term strategic CRO partner? With technology and the market both priming CROs to step in as industry innovators, what attributes should sponsors look for in 'best-in-class' strategic partners?
In this webinar, we will explore:
- How successful collaborations between sponsors and CROs require skills in communication and relationship management
- How one critical element of successful partnership is transparency, from both a data and business process perspective
- How with the advent of cloud-based software, collaboration and analytics have the potential to revolutionize the traditional clinical trial workflow, encouraging proactive planning and breaking down organizational siloes
This webinar is applicable to:
- Sponsor and CRO roles responsible for site identification, feasibility assessment, selection and activation
- Sponsor and CRO roles responsible for collecting and evaluating trial metrics
Tuesday, February 27
1 pm ET
10 am PT
In 2014, Andrew took over the role of CEO for CROS NT after 2 years of serving as Vice President in which he was responsible for some of CROS NT's biggest milestones including business expansion through acquisitions in both the UK and the USA. Andrew began his working life with the Royal Air Force before making the move to the clinical trials business where he has over 18 years of experience. With a strong background in programming and data management, Andrew has worked in Senior Management and Director roles with multiple CROs in Europe and in the USA. He has studied business administration at Walden University, holds an MBA from Newcastle University, and is currently studying law at the Open University.
Head of Business Operations
Barry is a clinical trial and operations management expert. His experiences as an Oncology nurse, clinical trial coordinator and his senior management roles at Novartis, Roche, Merck, and AstraZeneca provides him with a well-rounded set of skills and experiences in the clinical trial space. His passion is transforming study management and trial execution processes through the creation of optimized business processes, which are supported by facilitating systems, which allow sponsor and investigator teams to meet their patient and clinical program goals faster and more efficiently.
Patients Can't Wait
Jeff Kasher is a known pharmaceutical development change expert with 28 years of experience at Eli Lilly. He is passionate for improving outcomes, bringing patients and research sites into the development process, and dramatically decreasing time to market. His expertise includes novel product development from bench through market launch, research and clinical trial leadership, innovation center start-up as well as new industry paradigm creation.
Jeff is President of Patients Can't Wait, a member of Advisory Boards for TrialReach, Be the Partner, goBalto, BlueCloud, and ZS Associates. He advises several multinational Pharmaceutical companies and CROs. He sits on the DPharm steering committee and faculty and is a member of Linking Leaders. In 2013, CenterWatch named Jeff one of the "20 Innovators Changing the Face of the Clinical Trials Industry." He received a B.S. in Chemistry from Franklin & Marshall College, a Ph.D. in Pharmacology from the State University of New York, and a Post-Doctoral Fellowship in Physiology at Yale University School of Medicine.